CA9 and benign prostatic hyperplasia: However, in the case of CA9, its expression in prostate cancer is inconsistent; CA9 is highly expressed in androgen-independent prostate cancer cell lines in hypoxia, but absent or moderate in primary prostate cancer and benign prostatic hypertrophy (BPH) [26,46,47,48,49].